Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials.

ABSTRACT:

Background

Lactulose is the first-line drug for hepatic encephalopathy (HE), but its acceptance widely differs between Western and Eastern studies. Patient preference for lactulose between different parts of the world has not been examined systematically.

Aim

To define the preferences and reasons behind acceptance of lactulose in patients from USA and India.

Methods

A discrete-choice questionnaire with six hypothetical scenarios was constructed. Situations 1-3 studied preference for lactulose vs no-lactulose, while 4-6 studied preference for high-dose vs low-dose lactulose varying the overt HE prevention at 6 months and adverse event rates in each situation. This was administered to outpatient cirrhotics without prior/current experience with lactulose after dedicated

SUBMITTER: Rathi S 

PROVIDER: S-EPMC5992302 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature